MedTrace Logo

Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer

NCT00688415 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2019-09-25

No results posted yet for this study

Summary

This is a multi-center, Phase I study of a new investigational drug, VTX-2337, that may stimulate the immune system to help fight cancer. The purpose of the study is to assess the safety of the investigational drug and to identify the highest dose that is well-tolerated. The pharmacology of VTX-2337 will also be evaluated.

Conditions

Interventions

DRUG

VTX-2337

Escalating doses of the investigational drug will be administered to cohorts of patients until the highest tolerated dose is identified.

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Amar Patel, MD · Celgene

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-07
Primary Completion
2010-08-31
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00688415 on ClinicalTrials.gov